Telix Pharmaceuticals Limited (NASDAQ:TLX) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Key Points

• Analysts give Telix Pharmaceuticals a “Moderate Buy” consensus: Of eight analysts, four rate the stock a buy, one a strong buy, two recommend holding, and one rates it a sell. The average 12-month price target is $20.40.
• Institutional interest has increased: Several investment firms recently initiated or expanded their positions, including Private Advisor Group, Lazard Asset Management, and Portland Investment Counsel.
• Shares recently traded at $11.52, up 8.3%: The stock remains above its 50-day and 200-day moving averages and has traded between $6.28 and $12.60 over the past year.

Shares of Telix Pharmaceuticals Limited (NASDAQ:TLX - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the eight analysts that are presently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, two have issued a hold recommendation, four have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $20.40.

Several equities analysts have commented on the stock. HC Wainwright reiterated a "buy" rating and issued a $20.00 price objective on shares of Telix Pharmaceuticals in a report on Tuesday, July 7th. Weiss Ratings reaffirmed a "sell (d)" rating on shares of Telix Pharmaceuticals in a report on Friday, July 17th. Wedbush reaffirmed an "outperform" rating and set a $22.00 target price on shares of Telix Pharmaceuticals in a report on Monday, July 6th. Wall Street Zen upgraded shares of Telix Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Saturday, April 11th. Finally, Citigroup lowered their price target on shares of Telix Pharmaceuticals from $22.50 to $22.00 and set a "buy" rating on the stock in a report on Tuesday, July 7th.

Hedge Funds Weigh In On Telix Pharmaceuticals

A number of large investors have recently made changes to their positions in TLX. Millennium Management LLC bought a new stake in Telix Pharmaceuticals in the 3rd quarter valued at $1,883,000. Hennion & Walsh Asset Management Inc. bought a new position in Telix Pharmaceuticals during the 2nd quarter worth $1,731,000. Portland Investment Counsel Inc. increased its position in Telix Pharmaceuticals by 108.0% during the 4th quarter. Portland Investment Counsel Inc. now owns 266,200 shares of the company's stock worth $2,063,000 after buying an additional 138,200 shares during the period. Lazard Asset Management LLC lifted its holdings in shares of Telix Pharmaceuticals by 118.6% during the fourth quarter. Lazard Asset Management LLC now owns 250,517 shares of the company's stock worth $1,876,000 after buying an additional 135,893 shares in the last quarter. Finally, Private Advisor Group LLC lifted its holdings in shares of Telix Pharmaceuticals by 276.3% during the first quarter. Private Advisor Group LLC now owns 174,415 shares of the company's stock worth $1,669,000 after buying an additional 128,070 shares in the last quarter.

Telix Pharmaceuticals Trading Up 8.3%

TLX opened at $11.52 on Friday. The stock's fifty day simple moving average is $10.44 and its 200 day simple moving average is $9.35. Telix Pharmaceuticals has a 1-year low of $6.28 and a 1-year high of $12.60. The company has a debt-to-equity ratio of 1.08, a quick ratio of 1.27 and a current ratio of 1.43.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals NASDAQ: TLX is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source